SecBot SecBot
8-K ·Filed Apr 27, 2026

BMRN

BIOMARIN PHARMACEUTICAL INC
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago SEC0001193125-26-179243
8-K material event: Items 1.01, 2.01
Actionable Insight ▲ Bullish

Monitor Biogen's integration of Amicus' commercial operations and upcoming Q1 earnings call for updated 2026 guidance. The acquisition significantly expands Biogen's rare disease portfolio with two commercial products, potentially driving revenue growth, but increases leverage that will need to be managed.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$53.62
T+0 close · Apr 27, 2026 · via day close
Latest settled
+8.91%
T+60 · $58.40
Vs SPY
+4.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $53.62entry
  2. T+1 · 7mo ago −0.63%α −0.15% · $53.28
  3. T+5 · 7mo ago +3.36%α +2.96% · $55.42
  4. T+20 · 6mo ago −1.39%α −6.34% · $52.88
  5. T+60 · 4mo ago +8.91%α +4.40% · $58.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen completed its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction, funding the deal through a $2.8 billion term loan package and previously issued notes. The acquisition adds Fabry and Pompe disease treatments to Biogen's portfolio, strengthening its rare disease focus.

Key Financial Metrics

Deal Value
$4.8B
Deal Type
acquisition

Key Facts

  • Completed acquisition of Amicus Therapeutics for $4.8 billion in all-cash transaction
  • Acquired Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease) treatments
  • Financed through $2.0 billion Term Loan B, $800 million Term Loan A, and $850 million 2034 Notes
  • Existing credit agreement was repaid and terminated
  • New senior secured credit facilities have five- to seven-year maturities

Financial Impact

$4.8 billion acquisition funded by $2.8 billion in new term loans and existing capital

debtacquisitionrevenue

Risk Factors

  • Integration challenges between the two companies
  • Increased debt burden from the acquisition financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (31 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-179243
Document: d113922d8k.htm0001193125-26-179243
Document: d113922dex991.htm0001193125-26-179243
Document: d113922dex41.htm0001193125-26-179243
Document: 0001193125-26-179243-index-headers.html0001193125-26-179243
Document: 0001193125-26-179243-index.html0001193125-26-179243
Document: 0001193125-26-179243.txt0001193125-26-179243

Track record

16 reports on BMRN

Performance horizon

1 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +3.49% at T+1 after the Aug 18, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
  2. Nov 2, 202614d ago 8-K Bearish 6/10 Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
  3. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
  4. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
  5. Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
  6. Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
  7. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
  8. Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
  9. Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
  10. Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (9h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026